Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04202835 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ATG Plus PTCy vs ATG for CGVHD Prophylaxis

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Primary completion date changed from estimate of Oct 13, 2024 to May 18, 2024 · Completion date: Dec 31, 2024 to Feb 7, 2026 · Start date: Oct 13, 2020 to Oct 14, 2020 · 1 morev7 Show 4 more changesShow less
    • Primary completion date changed from estimate of Oct 13, 2024 to May 18, 2024
    • Completion date: Dec 31, 2024 to Feb 7, 2026
    • Start date: Oct 13, 2020 to Oct 14, 2020
    • Site details revised at 9 of 9 sites
  2. Re-verified, no change to tracked fieldsv6
  3. Primary completion date: Jun 30, 2021 to Oct 13, 2024 Completion date: Dec 31, 2021 to Dec 31, 2024 · Eligibility criteria expanded, about 38 wordsv5 Show 2 more changesShow less
    • Completion date: Dec 31, 2021 to Dec 31, 2024
    • Eligibility criteria expanded, about 38 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 7 to 9 Eligibility criteria expanded, about 83 wordsv4 Show 1 more changeShow less
    • Eligibility criteria expanded, about 83 words

    See this version in full on ClinicalTrials.gov ↗

  5. Site details revised at 1 of 7 sites Eligibility criteria shortened, about 3 wordsv3 Show 1 more changeShow less
    • Eligibility criteria shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  6. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Feb 1, 2020 to Oct 13, 2020 · Study sites: 0 to 7v2 Show 2 more changesShow less
    • Start date changed from estimate of Feb 1, 2020 to Oct 13, 2020
    • Study sites: 0 to 7
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.
Trial Details
NCT Number NCT04202835
Lead Sponsor McMaster University
Collaborators: Cell Therapy Transplant Canada, Sanofi, Ozmosis Research Inc.
Conditions Acute Leukemia, Myelodysplasia, Chronic Graft-versus-host-disease
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov